^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    telatinib (BAY 57- 9352)

    i
    Other names: BAY 57- 9352, EOC315, TEL0805
    Associations

    News

    Trials
    Company:
    EddingPharm
    Drug class:
    c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=16, Completed, Andrew Hendifar, MD | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    8ms
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Andrew Hendifar, MD | Trial completion date: Feb 2025 --> Feb 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    8ms
    Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis. (PubMed, Cancer Cell Int)
    We confirmed that irinotecan-related regulators, especially FSTL3, have effective prognostic value in CRC and speculated that FSTL3 may promote CRC progression and affect ferroptosis, which is beneficial for identifying candidate targeted irinotecan-related regulators and accurate individualized treatment strategies for CRC.
    Journal
    |
    MSI (Microsatellite instability) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HSPB1 (Heat shock 27kDa protein 1) • E2F1 (E2F transcription factor 1)
    |
    irinotecan • telatinib (BAY 57- 9352)
    1year
    Discovery of Small Molecule Inhibitors Targeting CTNNB1 (β-catenin) for Endometrial cancer: Employing 3D QSAR, Drug-Likeness Assessment, ADMET Predictions, Molecular Docking and Simulation. (PubMed, Curr Med Chem)
    Through a comprehensive screening process employing in silico drug design methods, this study successfully identified five potential human anticancer drug candidates targeting the beta-catenin protein. These findings offer a foundation for further experimental validation and development towards the treatment of EC.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    pazopanib • Mektovi (binimetinib) • telatinib (BAY 57- 9352)
    1year
    Analysis of the role of CHPF in colorectal cancer tumorigenesis and immunotherapy based on bioinformatics and experiments. (PubMed, Discov Oncol)
    CHPF could promote the proliferation and migration of CRC cells and lead to poor prognosis, possibly through wnt pathways as well as changes in TME. Patients with high expression of CHPF had poor efficacy in immunotherapy, which might be related to Tregs cell infiltration. Above all, it might offer more reliable guidance for future immunotherapy.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • CHPF (Chondroitin Polymerizing Factor)
    |
    MSI-H/dMMR
    |
    Mekinist (trametinib) • serdemetan (JNJ-26854165) • telatinib (BAY 57- 9352)
    over1year
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Andrew Hendifar, MD | Trial completion date: Feb 2024 --> Feb 2025
    Trial completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    almost3years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Andrew Hendifar, MD | Recruiting --> Active, not recruiting | N=45 --> 17
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    over3years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Andrew Hendifar, MD | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    over3years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Andrew Hendifar, MD | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    over4years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Andrew Hendifar, MD | Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Feb 2024 | Initiation date: May 2021 --> Aug 2021 | Trial primary completion date: Nov 2023 --> Feb 2024
    Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    over4years
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Andrew Hendifar, MD
    Clinical • New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)